EGFR Antibody

Phase 2Small molecule

SSun Yat-Sen University Cancer Center

EGFR Antibody is one of 53 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaRecruiting

Nasopharyngeal CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

90 competitors in Nasopharyngeal Carcinoma

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 3

7 2

Tuoyi

CCoherus Oncology, Inc.

Phase 3

20 3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

20 4

Taxotere

AAvyxa

Phase 3

15 5

Tuoyi

SSun Yat-sen University

Phase 3

11 6

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

10 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

6 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

6 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 10

Induction Phase1

Genmab

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1/2Recruiting

Nasopharyngeal Carcinoma

NCT06802835

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Recruiting·SSun Yat-Sen University Cancer Center·Phase 1/2·NCT06802835·148 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EGFR Antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EGFR Antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EGFR Antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-Sen University Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-Sen University Cancer Center

EGFR Antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News